Drugs / GLIX1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07464925 | Apr 2026 → Jun 2027 expected | brain glioblastoma | Tetragon Biosciences Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-10 | BioLineRx, Ltd. | Results BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) biolinerx.com ↗
Notably, our preclinical data demonstrating the potent anti-tumor effect of GLIX1 in GBM across multiple in-vivo studies, including two orthotopic cell-derived xenograft GBM models as well as a temozolomide-resistant patient derived xenograft model, will be featured in a mini-oral presentation. |
| 2026-08-31 | BioLineRx, Ltd. | Results BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update biolinerx.com ↗
In this regard, we announced new data in a temozolomide-resistant patient-derived xenograft (PDX) GBM in-vivo model, in which GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect. |
| 2026-07-08 | BioLineRx, Ltd. | Results BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model biolinerx.com ↗ |
| 2026-05-27 | BioLineRx, Ltd. | Results BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update biolinerx.com ↗
We are also very encouraged by compelling new pre-clinical data showing that GLIX1 demonstrated robust dose-dependent tumor-growth inhibition and survival benefit in orthotopic cell-derived xenograft (CDX) GBM models. |
| 2026-05-19 | BioLineRx, Ltd. | Results BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts biolinerx.com ↗
In the three orthotopic CDX studies, significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels. |
| 2025-11-17 | BioLineRx, Ltd. | Regulatory BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types biolinerx.com ↗
today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent, entitled, 'Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies' |
All press releases naming this drug 11 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLIX1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07464925 ↗ |
| Action | Activate | “enhancing Tet methylcytosine dioxygenase 2 (TET2) activity” NCT07464925 ↗ |
| Modality | Small molecule | “GLIX1 is a small molecule administered PO (per os, i.e., orally)” NCT07464925 ↗ |
| Route | Oral | “Administered orally, once daily, in cycles of 28 days” NCT07464925 ↗ |
| Target | TET2 | “enhancing Tet methylcytosine dioxygenase 2 (TET2) activity” NCT07464925 ↗ |